BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.58M | -4.83M | -5.53M | -6.63M | -10.35M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.02M | 2.66M | 3.38M | 4.08M | 8.27M |
| Change in Net Operating Assets | 940.80K | 1.83M | 1.61M | 1.77M | 1.14M |
| Cash from Operations | -622.70K | -339.50K | -543.00K | -780.20K | -935.80K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -778.50K | -778.50K | -- | -- | -- |
| Cash from Investing | -778.50K | -778.50K | -- | -- | -- |
| Total Debt Issued | 13.80K | -- | -- | -- | -- |
| Total Debt Repaid | -33.40K | -33.40K | -- | -- | -- |
| Issuance of Common Stock | 2.41M | 1.68M | 1.63M | 917.10K | 1.27M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -25.30K |
| Cash from Financing | 1.76M | 1.22M | 1.21M | 678.00K | 924.90K |
| Foreign Exchange rate Adjustments | 1.10K | -2.00K | -3.00K | -2.40K | -16.90K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Net Change in Cash | 362.80K | 100.00K | 661.70K | -104.50K | -27.60K |
